Veerhealth Care Ltd
Incorporated in 1992, Veer Healthcare Ltd (formerly Niyati Leasing Ltd) is engaged in
the business of trading and manufacturing and marketing research based ayurvedic medicines
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Reg. 34 (1) Annual Report.
22 Aug - Annual Report 2024-25; 33rd AGM on Sep 30, 2025; secretarial auditor appointed (₹55,000); director reappointment and continuation
- Shareholder Meeting - AGM On September 30, 2025 22 Aug
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
22 Aug - Repeat USA export order worth ₹0.20 Crore received; to be executed within 30 days.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
21 Aug - Received Rs.0.20 Cr international order to manufacture/supply oral care; 30-day execution; following USFDA approval on 16-May-2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
13 Aug - Q1 FY26: 112% income growth; USFDA clearance enables US exports; ₹0.48 Cr order; aims ₹100 Cr revenue in 36 months.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025TranscriptNotesPPT
-
Sep 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT
-
Feb 2024TranscriptPPT
Service Offered[1]
Contract Manufacturing, White Labelling, Product Development and Custom Formulation